[Vitamin D therapy in predialysis renal failure].
Vitamin D therapy is indicated in predialysis renal failure patients with secondary hyperparathyroidism caused by vitamin D deficiency. Vitamin D therapy brings about suppression of PTH and ameliorates oseitis fibrosa. To prevent aggravation of renal function, starting with small dose (0.25 microg/day) of calcitriol or alfacalcidol and dose adjustment of vitamin D with careful monitoring of serum calcium, phosphorus and PTH are recommended.
Ando
Ryoichi
R
Department of Nephrology, Musashino Red Cross Hospital.
D000284:Administration, Oral; D002117:Calcitriol / Q000008:administration & dosage*; D002118:Calcium / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D008991:Monitoring, Physiologic; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism; D010758:Phosphorus / Q000097:blood; D017410:Practice Guidelines as Topic; D020551:Pulse Therapy, Drug; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium; C008088:alfacalcidol